Grimm et al. BMC Cancer 2010, 10:82 http://www.biomedcentral.com/1471-2407/10/82 Cugnenc PH, Trajanoski Z, Fridman WH, Pages F: Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome. Science 2006, 5795:1960-1964. 30. Michael-Robinson JM, Pandeya N, Walsh MD, Biemer-Huttmann AE, Eri RD, Buttenshaw RL, Lincoln D, Clouston AD, Jass JR, Radford-Smith GL: Characterization of Tumour-Infiltrating Lymphocytes and Apoptosis in Colitis-Associated Neoplasia: Comparison With Sporadic Colorectal Cancer. J Pathol 2006, 3:381-387. 31. Clarke SL, Betts GJ, Plant A, Wright KL, El Shanawany TM, Harrop R, Torkington J, Rees BI, Williams GT, Gallimore AM, Godkin AJ: CD4+CD25 +FOXP3+ Regulatory T Cells Suppress Anti-Tumor Immune Responses in Patients With Colorectal Cancer. PLoS One 2006, e129. 32. Loddenkemper C, Schernus M, Noutsias M, Stein H, Thiel E, Nagorsen D: In Situ Analysis of FOXP3+ Regulatory T Cells in Human Colorectal Cancer. J Transl Med 2006, 52. 33. Casares N, Arribillaga L, Sarobe P, Dotor J, Lopez-Diaz dC, Melero I, Prieto J, Borras-Cuesta F, Lasarte JJ: CD4+/CD25+ Regulatory Cells Inhibit Activation of Tumor-Primed CD4+ T Cells With IFN-Gamma-Dependent Antiangiogenic Activity, As Well As Long-Lasting Tumor Immunity Elicited by Peptide Vaccination. J Immunol 2003, 11:5931-5939. 34. Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, Platell C, Iacopetta B: Tumor-Infiltrating FOXP3+ T Regulatory Cells Show Strong Prognostic Significance in Colorectal Cancer. J Clin Oncol 2009, 2:186-192. 35. Chaput N, Louafi S, Bardier A, Charlotte F, Vaillant JC, Menegaux F, Rosenzwajg M, Lemoine F, Klatzmann D, Taieb J: Identification of CD8 +CD25+Foxp3+ Suppressive T Cells in Colorectal Cancer Tissue. Gut 2009, 4:520-529. 36. Mosmann TR, Sad S: The Expanding Universe of T-Cell Subsets: Th1, Th2 and More. Immunol Today 1996, 3:138-146. 37. Romagnani S: The Th1/Th2 Paradigm. Immunol Today 1997, 6:263-266. 38. Cui G, Florholmen J: Polarization of Cytokine Profile From Th1 into Th2 Along Colorectal Adenoma-Carcinoma Sequence: Implications for the Biotherapeutic Target?. Inflamm Allergy Drug Targets 2008, 2:94-97. 39. Beatty G, Paterson Y: IFN-Gamma-Dependent Inhibition of Tumor Angiogenesis by Tumor-Infiltrating CD4+ T Cells Requires Tumor Responsiveness to IFN-Gamma. J Immunol 2001, 4:2276-2282. 40. Ikeda H, Old LJ, Schreiber RD: The Roles of IFN Gamma in Protection Against Tumor Development and Cancer Immunoediting. Cytokine Growth Factor Rev 2002, 2:95-109. 41. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Galon J: Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer. N Engl J Med 2005, 25:2654-2666. 42. Hirata N, Yanagawa Y, Satoh M, Ogura H, Ebihara T, Noguchi M, Matsumoto M, Togashi H, Seya T, Onoe K, Iwabuchi K: Dendritic Cell- Derived TNF-Alpha Is Responsible for Development of IL-10-Producing CD4+ T Cells. Cell Immunol 2010, 1:37-41. 43. Vohra N, Verhaegen M, Martin L, Mackay A, Pilon-Thomas S: TNF-Alpha- Treated DC Exacerbates Disease in a Murine Tumor Metastasis Model. Cancer Immunol Immunother 2009. 44. Radfar S, Martin H, Tilkin-Mariame AF: [Tumor Escape Mechanism Involving Fas and Fas-L Molecules in Human Colorectal Tumors]. Gastroenterol Clin Biol 2000, 12:1191-1196. 45. Ryan AE, Shanahan F, O’Connell J, Houston AM: Fas Ligand Promotes Tumor Immune Evasion of Colon Cancer in Vivo. Cell Cycle 2006, 3:246-249. 46. Sheehan KM, O’Donovan DG, Fitzmaurice G, O’Grady A, O’Donoghue DP, Sheahan K, Byrne MF, Conroy RM, Kay EW, Murray FE: Prognostic Relevance of Fas (APO-1/CD95) Ligand in Human Colorectal Cancer. Eur J Gastroenterol Hepatol 2003, 4:375-380. Pre-publication history The pre-publication history for this paper can be accessed here:http://www. biomedcentral.com/1471-2407/10/82/prepub doi:10.1186/1471-2407-10-82 Cite this article as: Grimm et al.: Evaluation of immunological escape mechanisms in a mouse model of colorectal liver metastases. BMC Cancer 2010 10:82. Page 11 of 11 Submit your next manuscript to BioMed Central and take full advantage of: • Convenient online submission • Thorough peer review • No space constraints or color ﬁgure charges • Immediate publication on acceptance • Inclusion in PubMed, CAS, Scopus and Google Scholar • Research which is freely available for redistribution Submit your manuscript at www.biomedcentral.com/submit